Results 91 to 100 of about 16,400 (171)

Can we stop nucleoside analogues before HBsAg loss?

, 2019
Most of the current guidelines and the existing data suggest that long-term therapy with nucleos(t)ide analogue(s) [NA(s)] may be stopped in carefully selected chronic hepatitis B patients who remain HBsAg positive.
Papatheodoridis, G., Papatheodoridi, M.
core  

Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. [PDF]

EBioMedicine, 2021
Xiong S, Zhu D, Liang B, Li M, Pan W, He J, Wang H, Sutter K, Dittmer U, Lu M, Liu D, Yang D, Liu J, Zheng X.   +13 more
europepmc   +1 more source

High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy [PDF]

Objective: Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but this rarely occurs with currently approved therapies.
Liu, Y, Dou, X, Xie, J, Jiang, Y, Rao, H, Sun, A, Hou, J, Ma, H, Xie, Q, Yang, Y, Niu, J, Naoumov, NV, Liang, X, Gao, H, Sun, J, Yang, S, Zhao, S, Xia, Q, Yu, Y, Fan, R, Shang, J, Yin, X   +21 more
core  

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array. [PDF]

Front Immunol, 2021
Gu S, Liu Z, Lin L, Zhong S, Ma Y, Li X, Ye G, Wen C, Li Y, Tang L.   +9 more
europepmc   +1 more source

Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment. [PDF]

Sci Rep, 2021
Narayanan S, Au VB, Khakpoor A, Yan C, Ahl PJ, Kaliaperumal N, Lee B, Xiang WW, Wang J, Lee C, Tay A, Lim SG, Connolly JE.   +12 more
europepmc   +1 more source

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. [PDF]

Infect Drug Resist, 2022
Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J.   +9 more
europepmc   +1 more source

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment. [PDF]

Front Cell Infect Microbiol
Cao W, Xie S, Hao H, Deng W, Zhang L, Lu Y, Liu R, Wang S, Li X, Zhang Z, Wei X, Gao Z, Yao L, Wang S, Gao Y, Wang Y, Xu M, Hu L, Xie Y, Li M.   +19 more
europepmc   +1 more source

HBsAg loss in recipients with chronic hepatitis B after allogeneic hematopoietic stem-cell transplantation: a retrospective cohort study exploring kinetic dynamics. [PDF]

BMC Infect Dis
Wang Q, Huang P, Zhang Q, Liu Y, Zang Q, Zhu C, Wang Y, He Y.   +7 more
europepmc   +1 more source

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection. [PDF]

CPT Pharmacometrics Syst Pharmacol
Hanan NJ, Zierhut ML, Nader A, Mahajan A, Kaur A, Kumar K, Dixon SA, Das J, Magee M, Theodore D, Gielen V.   +10 more
europepmc   +1 more source

Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients

Introduction: Nucleos(t)ide analogues (NAs) discontinuation in HBeAg-negative chronic hepatitis B (CHB) aims at increasing functional cure rates. However, clinical outcomes and predictive factors for HBsAg loss or re-treatment are affected by the ...
Rodríguez Tajes, Sergio, Herms Rubió, Queralt, Lens García, Sabela, Pocurull Aparicio, Anna, Forns Bernhardt, Xavier   +4 more
core   +1 more source